A Long-term Safety Study of Once-daily Travatan
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00051168|
Recruitment Status : Completed
First Posted : January 7, 2003
Results First Posted : April 12, 2010
Last Update Posted : October 7, 2011
|Condition or disease||Intervention/treatment||Phase|
|Glaucoma, Open-angle Ocular Hypertension||Drug: Travatan||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||502 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Long-term Safety Study of Once-daily TRAVATAN|
|Study Start Date :||January 2006|
|Primary Completion Date :||March 2009|
Travoprost (0.004%) 1 drop each eye once daily
- Mean Intraocular Pressure [ Time Frame: At 5 years. ]
Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken.
All IOP measurements were performed with a Goldmann applanation tonometer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00051168
|United States, Texas|
|Fort Worth, Texas, United States|